Crossref
Less is more: lessons from adding antiangiogenesis to 1L chemo-immunotherapy in non-small cell lung cancer (LEAP-006)
AME Clinical Trials Review · 2026-06 · 4 · 26-26
DOI: 10.21037/actr-25-120 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-06. Verfasst von Federico Monaca und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Monaca, F., Gómez-Randulfe, I., & Califano, R. (2026). Less is more: lessons from adding antiangiogenesis to 1L chemo-immunotherapy in non-small cell lung cancer (LEAP-006). AME Clinical Trials Review, 4, 26-26. https://doi.org/10.21037/actr-25-120
Vancouver
Monaca F, Gómez-Randulfe I, Califano R. Less is more: lessons from adding antiangiogenesis to 1L chemo-immunotherapy in non-small cell lung cancer (LEAP-006). AME Clinical Trials Review. 2026;4:26-26. doi:10.21037/actr-25-120
BibTeX
@article{Monaca2026,
author = {Monaca, Federico and Gómez-Randulfe, Igor and Califano, Raffaele},
title = {Less is more: lessons from adding antiangiogenesis to 1L chemo-immunotherapy in non-small cell lung cancer (LEAP-006)},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {26--26},
doi = {10.21037/actr-25-120}
}
EUVIMED